INNT - Innovate Biopharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
0
0
1,883
4,065
8,266
Cost of Revenue
-
-
1,947
3,329
7,840
Gross Profit
-
0
-64
736
426
Operating Expenses
Research Development
9,959
7,559
190
270
333
Selling General and Administrative
10,724
10,665
6,412
6,409
6,553
Total Operating Expenses
20,683
18,224
6,602
6,679
6,886
Operating Income or Loss
-20,683
-18,224
-6,666
-5,943
-6,460
Interest Expense
1,889
6,152
93
825
1,381
Total Other Income/Expenses Net
-
50
-1,166
557
-898
Income Before Tax
-22,355
-24,162
-7,925
-6,211
-8,739
Income Tax Expense
0
0
0
2
2
Income from Continuing Operations
-22,355
-24,162
-7,925
-6,213
-8,741
Net Income
-22,355
-24,162
-7,925
-6,213
-8,741
Net Income available to common shareholders
-22,355
-24,162
-8,821
-6,213
-8,741
Reported EPS
Basic
-
-0.98
-9.36
-11.20
-16.45
Diluted
-
-0.98
-9.36
-11.20
-16.45
Weighted average shares outstanding
Basic
-
24,762
942
552
531
Diluted
-
24,762
942
552
531
EBITDA
-
-17,991
-7,701
-5,255
-7,304